Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol

Fig. 1

PK and PD simulation of two metronomic protocols. Comparative model prediction for a median PK (a) profile, neutrophil count (b) and tumor weight (c) profiles with inter-individual variability, for 160 days, of two different metronomic protocols: Briasoulis et al. schedule (i.e., 50 mg on D1, D3, D5) vs the computational-based schedule Vinorelbine Theoretical Protocol (i.e.,60, 30, 60 mg on D1, D2, D4). Whereas similar tolerance is predicted between both schedules, the VTP schedule could lead to a much greater impact on tumor growth, with less variability

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us